Study summary
A year of immunotherapy after chemoradiation cut relapses by almost half
86.9%event-free at 3 years, vs 77.3% with standard treatment
What was tested
Camrelizumab, a PD-1 immunotherapy, given for a year after standard chemoradiotherapy, against chemoradiotherapy alone, for locally advanced nasopharyngeal carcinoma.
What they found
- 3-year event-free survival was 86.9% vs 77.3% (hazard ratio 0.56).
- Severe side effects were more common (11.2% vs 3.2%).
- Quality of life did not worsen.
What it means
Adds to evidence that immunotherapy belongs in the curative treatment of nasopharyngeal carcinoma, not just advanced disease.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.